{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT04729114",
            "orgStudyIdInfo": {
                "id": "PRL-02-1001"
            },
            "organization": {
                "fullName": "Astellas Pharma Inc",
                "class": "INDUSTRY"
            },
            "briefTitle": "Open-label, Multicenter Study of Intramuscular PRL-02 Depot in Patients With Advanced Prostate Cancer",
            "officialTitle": "Phase 1/2a, Open-Label, Multicenter Study of Intramuscular PRL-02 Depot in Patients With Advanced Prostate Cancer",
            "therapeuticArea": [
                "Oncology and Hematology",
                "Other"
            ],
            "study": "open-label-multicenter-study-of-intramuscular-prl-depot-in-patients-with-advanced-prostate-cancer"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-06",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2021-06-14",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-12-31",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-04-30",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2021-01-15",
            "studyFirstSubmitQcDate": "2021-01-27",
            "studyFirstPostDateStruct": {
                "date": "2021-01-28",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-06-10",
            "lastUpdatePostDateStruct": {
                "date": "2024-06-11",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Astellas Pharma Global Development, Inc.",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "A Phase 1/2a, open-label, multicenter study of intramuscular (i.m.) PRL-02 depot in participants with advanced prostate cancer.",
            "detailedDescription": "Phase 1/2a, open-label, multicenter study of intramuscular (i.m.) PRL-02 depot in participants with castration-sensitive prostate cancer (CSPC) and metastatic castration-resistant prostate cancer (mCRPC). In Phase 1 (Dose Escalation), participants will receive escalating doses of i.m. PRL-02 in 84-day treatment cycles combined with daily oral steroid.\n\nIn Phase 2a (Dose Expansion), participants with metastatic castration-sensitive prostate cancer (mCSPC) and mCRPC will receive i.m. PRL-02 at one or more recommended Phase 2 doses (RP2Ds) selected from Phase 1 in 84-day treatment cycles in combination with dexamethasone and docetaxel (Group F1) or in combination with dexamethasone (Groups F2, G). In both phases, participants will undergo scheduled periodic assessments of prostate specific antigen (PSA), testosterone and progesterone levels in the blood."
        },
        "conditionsModule": {
            "conditions": [
                "Prostate Cancer",
                "mCRPC",
                "mCSPC"
            ],
            "keywords": [
                "Testosterone",
                "Testosterone suppression",
                "metastatic castrate sensitive prostate cancer",
                "metastatic castrate resistant prostate cancer",
                "metastatic disease",
                "prostate cancer",
                "mCSPC",
                "mCRPC",
                "abiraterone",
                "abiraterone decanoate",
                "abiraterone acetate",
                "Phase 1/2a",
                "Propella"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1",
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "interventionModelDescription": "This is a 3+3 dose escalation study design with a dose expansion phase once a Phase 2 dose is identified.",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 100,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Cohort 1",
                    "type": "EXPERIMENTAL",
                    "description": "180 mg PRL-02 + dexamethasone or prednisone",
                    "interventionNames": [
                        "Drug: PRL-02 injection",
                        "Drug: prednisone",
                        "Drug: dexamethasone"
                    ]
                },
                {
                    "label": "Cohort 2",
                    "type": "EXPERIMENTAL",
                    "description": "360 mg PRL-02 + dexamethasone or prednisone",
                    "interventionNames": [
                        "Drug: PRL-02 injection",
                        "Drug: prednisone",
                        "Drug: dexamethasone"
                    ]
                },
                {
                    "label": "Cohort 3",
                    "type": "EXPERIMENTAL",
                    "description": "720 mg PRL-02 + dexamethasone or prednisone",
                    "interventionNames": [
                        "Drug: PRL-02 injection",
                        "Drug: prednisone",
                        "Drug: dexamethasone"
                    ]
                },
                {
                    "label": "Cohort 4",
                    "type": "EXPERIMENTAL",
                    "description": "1260 mg PRL-02 + dexamethasone or prednisone",
                    "interventionNames": [
                        "Drug: PRL-02 injection",
                        "Drug: prednisone",
                        "Drug: dexamethasone"
                    ]
                },
                {
                    "label": "Cohort 5",
                    "type": "EXPERIMENTAL",
                    "description": "1800 mg PRL-02 + dexamethasone or prednisone",
                    "interventionNames": [
                        "Drug: PRL-02 injection",
                        "Drug: prednisone",
                        "Drug: dexamethasone"
                    ]
                },
                {
                    "label": "Phase 1 Expansion Group D",
                    "type": "EXPERIMENTAL",
                    "description": "Prior abiraterone",
                    "interventionNames": [
                        "Drug: PRL-02 injection",
                        "Drug: dexamethasone"
                    ]
                },
                {
                    "label": "Phase 1 Expansion Group E",
                    "type": "EXPERIMENTAL",
                    "description": "Prior enzalutamide, apalutamide and/or darolutamide",
                    "interventionNames": [
                        "Drug: PRL-02 injection",
                        "Drug: dexamethasone"
                    ]
                },
                {
                    "label": "Phase 2a Dose Expansion Group F1",
                    "type": "EXPERIMENTAL",
                    "description": "Dosing at recommended Phase 2 dose (RP2D); high volume mCSPC",
                    "interventionNames": [
                        "Drug: PRL-02 injection",
                        "Drug: dexamethasone",
                        "Drug: docetaxel infusion"
                    ]
                },
                {
                    "label": "Phase 2a Dose Expansion Group F2",
                    "type": "EXPERIMENTAL",
                    "description": "Dosing at RP2D; low volume mCSPC",
                    "interventionNames": [
                        "Drug: PRL-02 injection",
                        "Drug: dexamethasone"
                    ]
                },
                {
                    "label": "Phase 2a Dose Expansion Group G",
                    "type": "EXPERIMENTAL",
                    "description": "Dosing at RP2D; mCRPC",
                    "interventionNames": [
                        "Drug: PRL-02 injection",
                        "Drug: dexamethasone"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "PRL-02 injection",
                    "description": "abiraterone decanoate for intramuscular injection",
                    "armGroupLabels": [
                        "Cohort 1",
                        "Cohort 2",
                        "Cohort 3",
                        "Cohort 4",
                        "Cohort 5",
                        "Phase 1 Expansion Group D",
                        "Phase 1 Expansion Group E",
                        "Phase 2a Dose Expansion Group F1",
                        "Phase 2a Dose Expansion Group F2",
                        "Phase 2a Dose Expansion Group G"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "prednisone",
                    "description": "5 mg once daily or twice daily",
                    "armGroupLabels": [
                        "Cohort 1",
                        "Cohort 2",
                        "Cohort 3",
                        "Cohort 4",
                        "Cohort 5"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "dexamethasone",
                    "description": "0.5 mg administered once daily",
                    "armGroupLabels": [
                        "Cohort 1",
                        "Cohort 2",
                        "Cohort 3",
                        "Cohort 4",
                        "Cohort 5",
                        "Phase 1 Expansion Group D",
                        "Phase 1 Expansion Group E",
                        "Phase 2a Dose Expansion Group F1",
                        "Phase 2a Dose Expansion Group F2",
                        "Phase 2a Dose Expansion Group G"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "docetaxel infusion",
                    "description": "docetaxel administered via intravenous infusion",
                    "armGroupLabels": [
                        "Phase 2a Dose Expansion Group F1"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Safety (adverse events)",
                    "description": "Determine the incidence rates for adverse events using NCI CTCAE v5.0 grading through study completion, an average of 1 year",
                    "timeFrame": "Treatment"
                },
                {
                    "measure": "Determination of recommended Phase 2 dose (RP2D)",
                    "description": "Select RP2D of PRL-02 depot by evaluation of safety parameters up to 84 days",
                    "timeFrame": "Treatment"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Evaluate pharmacokinetics (PK) profile of PRL-02",
                    "description": "Determination of PK profiles of PRL-02 up to 84 days",
                    "timeFrame": "Treatment"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Histological evidence of adenocarcinoma of the prostate, including metastatic castration sensitive prostate cancer (mCSPC); castration sensitive prostate cancer (CSPC); castration sensitive prostate cancer (CSPC); metastatic castration resistant prostate cancer (mCRPC)\n* Undergone bilateral orchiectomy or ongoing GnRH agonist or antagonist therapy for at least 6 weeks prior to the first dose of study drug which must be continued throughout the study\n* Eastern Cooperative Oncology Group (ECOG) of 0 or 1\n* For Phase1 expansion Groups D \\& E only, received prior darolutamide, apalutamide, abiraterone or enzalutamide and have documented evidence of progression\n\nExclusion Criteria:\n\n* Known active central nervous system (CNS) metastases, except those who have been treated with surgery and/or radiation therapy, who are off pharmacologic doses of glucocorticoids, and who are neurologically stable.\n* Known additional malignancy beyond prostate cancer that required active treatment with the exception of: adequately treated basal cell carcinoma, squamous cell carcinoma of the skin, or in situ carcinoma of any type; adequately treated Stage I cancer from which the patient is currently in remission and has been in remission for \u22652 years; any other cancer from which the patient has been disease-free for \u22655 years\n* Clinically significant cardiac disease\n* Received chemotherapy within 2 weeks or 5 half-lives of first dose of study drug\n* Current treatment with enzalutamide, flutamide, nilutamide, bicalutamide, or any other androgen receptor (AR) blocking agents. Patients who have received anti-androgens or AR blocking agents must have discontinued bicalutamide \u22656 weeks and other antiandrogens \u22654 weeks prior to the first dose of PRL-02.\n* Prior treatment with estrogens within 12 weeks of the first dose of study drug\n* Need for systemic glucocorticoids greater than replacement doses; the use of topical, intraocular, inhalational, intranasal, or intra-articular glucocorticoids is permitted.\n* Required concomitant use of strong inducers of CYP3A4.\n* Known hypersensitivity to PRL-02, abiraterone, abiraterone decanoate, prednisone, or dexamethasone or any of their excipients or components.\n* Hemoglobin A1c (HbA1c) \\>10% in patients previously diagnosed with diabetes mellitus. HbA1c \\>8% in patients whose diabetes mellitus is previously undiagnosed. (Excluded patients may be rescreened after referral and evidence of improved control of their condition).\n* Body mass index \\> 40 kg/m\\^2",
            "healthyVolunteers": false,
            "sex": "MALE",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Astellas Pharma Global Development, Inc.",
                    "role": "CONTACT",
                    "phone": "800-888-7704",
                    "email": "Astellas.registration@astellas.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Central Contact",
                    "affiliation": "Astellas Pharma Global Development, Inc.",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "First Urology",
                    "status": "RECRUITING",
                    "city": "Jeffersonville",
                    "state": "Indiana",
                    "zip": "47130",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 38.27757,
                        "lon": -85.73718
                    }
                },
                {
                    "facility": "Wichita Urology Group",
                    "status": "RECRUITING",
                    "city": "Wichita",
                    "state": "Kansas",
                    "zip": "67226",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 37.69224,
                        "lon": -97.33754
                    }
                },
                {
                    "facility": "Chesapeake Urology",
                    "status": "RECRUITING",
                    "city": "Towson",
                    "state": "Maryland",
                    "zip": "21204",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 39.4015,
                        "lon": -76.60191
                    }
                },
                {
                    "facility": "XCancer Center Omaha/Urology Cancer Center",
                    "status": "RECRUITING",
                    "city": "Omaha",
                    "state": "Nebraska",
                    "zip": "68130",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 41.25626,
                        "lon": -95.94043
                    }
                },
                {
                    "facility": "Garden Sate Urology",
                    "status": "RECRUITING",
                    "city": "Morristown",
                    "state": "New Jersey",
                    "zip": "07960",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.79677,
                        "lon": -74.48154
                    }
                },
                {
                    "facility": "New Mexico Oncology Hematology Consultants Ltd",
                    "status": "RECRUITING",
                    "city": "Albuquerque",
                    "state": "New Mexico",
                    "zip": "87109",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 35.08449,
                        "lon": -106.65114
                    }
                },
                {
                    "facility": "Duke Cancer Center",
                    "status": "RECRUITING",
                    "city": "Durham",
                    "state": "North Carolina",
                    "zip": "27710",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 35.99403,
                        "lon": -78.89862
                    }
                },
                {
                    "facility": "Helios Clinical Research, LLC",
                    "status": "RECRUITING",
                    "city": "Middleburg Heights",
                    "state": "Ohio",
                    "zip": "44130",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 41.36144,
                        "lon": -81.81291
                    }
                },
                {
                    "facility": "Toledo Clinical Cancer Center",
                    "status": "WITHDRAWN",
                    "city": "Toledo",
                    "state": "Ohio",
                    "zip": "43623",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 41.66394,
                        "lon": -83.55521
                    }
                },
                {
                    "facility": "MidLantic Urology",
                    "status": "RECRUITING",
                    "city": "Bala-Cynwyd",
                    "state": "Pennsylvania",
                    "zip": "19004",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.00761,
                        "lon": -75.23407
                    }
                },
                {
                    "facility": "Carolina Urologic Research Center",
                    "status": "RECRUITING",
                    "city": "Myrtle Beach",
                    "state": "South Carolina",
                    "zip": "29572",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 33.68906,
                        "lon": -78.88669
                    }
                },
                {
                    "facility": "Urology Associates PC",
                    "status": "RECRUITING",
                    "city": "Nashville",
                    "state": "Tennessee",
                    "zip": "37209",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 36.16589,
                        "lon": -86.78444
                    }
                },
                {
                    "facility": "Urology San Antonio",
                    "status": "RECRUITING",
                    "city": "San Antonio",
                    "state": "Texas",
                    "zip": "78229",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 29.42412,
                        "lon": -98.49363
                    }
                },
                {
                    "facility": "University of Virginia Cancer Center",
                    "status": "RECRUITING",
                    "city": "Charlottesville",
                    "state": "Virginia",
                    "zip": "22908",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 38.02931,
                        "lon": -78.47668
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000011471",
                    "term": "Prostatic Neoplasms"
                }
            ],
            "ancestors": [
                {
                    "id": "D000005834",
                    "term": "Genital Neoplasms, Male"
                },
                {
                    "id": "D000014565",
                    "term": "Urogenital Neoplasms"
                },
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000005832",
                    "term": "Genital Diseases, Male"
                },
                {
                    "id": "D000091662",
                    "term": "Genital Diseases"
                },
                {
                    "id": "D000091642",
                    "term": "Urogenital Diseases"
                },
                {
                    "id": "D000011469",
                    "term": "Prostatic Diseases"
                },
                {
                    "id": "D000052801",
                    "term": "Male Urogenital Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M14335",
                    "name": "Prostatic Neoplasms",
                    "asFound": "Prostate Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10018",
                    "name": "Hypersensitivity",
                    "relevance": "LOW"
                },
                {
                    "id": "M12307",
                    "name": "Neoplasm Metastasis",
                    "relevance": "LOW"
                },
                {
                    "id": "M8946",
                    "name": "Genital Neoplasms, Male",
                    "relevance": "LOW"
                },
                {
                    "id": "M17315",
                    "name": "Urogenital Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M2876",
                    "name": "Genital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M8944",
                    "name": "Genital Diseases, Male",
                    "relevance": "LOW"
                },
                {
                    "id": "M2875",
                    "name": "Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M14333",
                    "name": "Prostatic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M27095",
                    "name": "Male Urogenital Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BXS",
                    "name": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC20",
                    "name": "Immune System Diseases"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000003907",
                    "term": "Dexamethasone"
                },
                {
                    "id": "D000011241",
                    "term": "Prednisone"
                },
                {
                    "id": "D000077143",
                    "term": "Docetaxel"
                }
            ],
            "ancestors": [
                {
                    "id": "D000000893",
                    "term": "Anti-Inflammatory Agents"
                },
                {
                    "id": "D000000932",
                    "term": "Antiemetics"
                },
                {
                    "id": "D000001337",
                    "term": "Autonomic Agents"
                },
                {
                    "id": "D000018373",
                    "term": "Peripheral Nervous System Agents"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000005765",
                    "term": "Gastrointestinal Agents"
                },
                {
                    "id": "D000005938",
                    "term": "Glucocorticoids"
                },
                {
                    "id": "D000006728",
                    "term": "Hormones"
                },
                {
                    "id": "D000006730",
                    "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"
                },
                {
                    "id": "D000018931",
                    "term": "Antineoplastic Agents, Hormonal"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                },
                {
                    "id": "D000050257",
                    "term": "Tubulin Modulators"
                },
                {
                    "id": "D000050256",
                    "term": "Antimitotic Agents"
                },
                {
                    "id": "D000050258",
                    "term": "Mitosis Modulators"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M7102",
                    "name": "Dexamethasone",
                    "asFound": "High",
                    "relevance": "HIGH"
                },
                {
                    "id": "M235549",
                    "name": "Dexamethasone acetate",
                    "relevance": "LOW"
                },
                {
                    "id": "M14121",
                    "name": "Prednisone",
                    "asFound": "Prospective",
                    "relevance": "HIGH"
                },
                {
                    "id": "M1668",
                    "name": "Docetaxel",
                    "asFound": "Management",
                    "relevance": "HIGH"
                },
                {
                    "id": "M451",
                    "name": "Abiraterone Acetate",
                    "relevance": "LOW"
                },
                {
                    "id": "M16509",
                    "name": "Testosterone",
                    "relevance": "LOW"
                },
                {
                    "id": "M4217",
                    "name": "Anti-Inflammatory Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M4251",
                    "name": "Antiemetics",
                    "relevance": "LOW"
                },
                {
                    "id": "M8881",
                    "name": "Gastrointestinal Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M9047",
                    "name": "Glucocorticoids",
                    "relevance": "LOW"
                },
                {
                    "id": "M9789",
                    "name": "Hormones",
                    "relevance": "LOW"
                },
                {
                    "id": "M9788",
                    "name": "Hormone Antagonists",
                    "relevance": "LOW"
                },
                {
                    "id": "M20966",
                    "name": "Antineoplastic Agents, Hormonal",
                    "relevance": "LOW"
                },
                {
                    "id": "M26197",
                    "name": "Tubulin Modulators",
                    "relevance": "LOW"
                },
                {
                    "id": "M26196",
                    "name": "Antimitotic Agents",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "Infl",
                    "name": "Anti-Inflammatory Agents"
                },
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "AnEm",
                    "name": "Antiemetics"
                },
                {
                    "abbrev": "Gast",
                    "name": "Gastrointestinal Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}